National Clinical Guideline Centre NICE clinical guideline 183 Drug allergy Diagnosis and management of drug allergy in adults, children and young people Clinical guideline 183 Appendices A–M September 2014 Final Commissioned by the National Institute for Health and Care Excellence Drug allergy Contents Disclaimer Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer. Copyright National Clinical Guideline Centre, 2014 Funding National Institute for Health and Care Excellence National Clinical Guideline Centre, 2014 Drug allergy Contents Contents Appendices........................................................................................................................................ 5 Appendix A: Scope...................................................................................................................... 5 Appendix B: Declarations of interest......................................................................................... 13 Appendix C: Clinical review protocols ....................................................................................... 21 Appendix D: Economic review protocol..................................................................................... 32 Appendix E: Clinical article selection......................................................................................... 34 Appendix F: Economic article selection .................................................................................... 42 Appendix G: Literature search strategies .................................................................................. 43 Appendix H: Clinical evidence tables ......................................................................................... 66 Appendix I: Economic evidence tables ................................................................................... 214 Appendix J: Forest plots......................................................................................................... 215 Appendix K: Excluded clinical studies...................................................................................... 219 Appendix L: Excluded economic studies ................................................................................. 260 Appendix M: Research recommendations ...................................................................... 261 References .................................................................................................................................... 271 National Clinical Guideline Centre, 2014 4 Drug allergy Scope Appendices Appendix A: Scope National Clinical Guideline Centre, 2014 5 Drug allergy Scope National Clinical Guideline Centre, 2014 6 Drug allergy Scope National Clinical Guideline Centre, 2014 7 Drug allergy Scope National Clinical Guideline Centre, 2014 8 Drug allergy Scope National Clinical Guideline Centre, 2014 9 Drug allergy Scope National Clinical Guideline Centre, 2014 10 Drug allergy Scope National Clinical Guideline Centre, 2014 11 Drug allergy Scope National Clinical Guideline Centre, 2014 12 Drug allergy Declarations of interest Appendix B: Declarations of interest B.1 Introduction ............................................................................................................................. 14 B.2 GDG members.......................................................................................................................... 14 B.2.1 Arden-Jones, Mike ......................................................................................................... 14 B.2.2 Cousins, David ................................................................................................................ 14 B.2.3 Doyle, Matthew ............................................................................................................. 14 B.2.4 Du Toit, George .............................................................................................................. 15 B.2.5 East, Mandy ................................................................................................................... 15 B.2.6 Ewan, Pamela................................................................................................................. 16 B.2.7 Larcombe, James ............................................................................................................ 16 B.2.8 Mundy, Nicola ................................................................................................................ 16 B.2.9 Nasser, Shuaib................................................................................................................ 17 B.2.10 Oborne, Alice ................................................................................................................. 17 B.2.11 Whitaker, Paul ............................................................................................................... 18 B.2.12 Williams, Andrew ........................................................................................................... 18 B.3 Co-optees ................................................................................................................................. 19 B.3.1 Brown, Nick .................................................................................................................... 19 B.3.2 Harper, Nigel J N ............................................................................................................ 19 B.3.3 Krishna, Thirumala ......................................................................................................... 20 B.4 All NCGC Staff .......................................................................................................................... 20 National Clinical Guideline Centre, 2014 13 Drug allergy Declarations of interest B.1 Introduction All members of the GDG and all members of the NCGC staff were required to make formal declarations of interest at the outset of each meeting, and these were updated at every subsequent meeting throughout the development process. No interests were declared that required actions. B.2 GDG members B.2.1 Arden-Jones, Mike GDG meeting Date Declaration of Interest Action Taken GDG Application None GDG Meeting 1 14/12/2012 No change GDG Meeting 2 25/01/2013 No change GDG Meeting 3 02/05/2013 No change GDG Meeting 4 07/06/2014 No change GDG Meeting 5 19/07/2014 No change GDG Meeting 6 16/09/2014 No change GDG Meeting 7 04/11/2013 No change GDG Meeting 8 05/11/2013 No change GDG Meeting 9 10/01/2014 No change GDG Meeting 10 31/01/2014 No change GDG Meeting 11 06/06/2014 No change B.2.2 Cousins, David GDG meeting Date Declaration of Interest Action Taken GDG Application None GDG Meeting 1 14/12/2012 No change GDG Meeting 2 25/01/2013 No change GDG Meeting 3 02/05/2013 No change GDG Meeting 4 07/06/2014 Apologies GDG Meeting 5 19/07/2014 No change GDG Meeting 6 16/09/2014 No change GDG Meeting 7 04/11/2013 No change GDG Meeting 8 05/11/2013 No change GDG Meeting 9 10/01/2014 No change GDG Meeting 10 31/01/2014 No change GDG Meeting 11 06/06/2014 No change B.2.3 Doyle, Matthew GDG meeting Date Declaration of Interest Action Taken GDG Application None GDG Meeting 1 14/12/2012 N/A due to delayed recruitment. GDG Meeting 2 25/01/2013 N/A due to delayed recruitment. GDG Meeting 3 02/05/2013 No change National Clinical Guideline Centre, 2014 14 Drug allergy Declarations of interest GDG meeting Date Declaration of Interest Action Taken GDG Meeting 4 07/06/2014 No change GDG Meeting 5 19/07/2014 Personal pecuniary interest: Paid for No action required. writing an article on allergic rhinitis for the Guidelines in Practice magazine. GDG Meeting 6 16/09/2014 No change GDG Meeting 7 04/11/2013 No change GDG Meeting 8 05/11/2013 No change GDG Meeting 9 10/01/2014 No change GDG Meeting 10 31/01/2014 Apologies GDG Meeting 11 06/06/2014 No change B.2.4 Du Toit, George GDG meeting Date Declaration of Interest Action Taken GDG Application None No action required. GDG Meeting 1 14/12/2012 Apologies GDG Meeting 2 25/01/2013 No change GDG Meeting 3 02/05/2013 No change GDG Meeting 4 07/06/2013 Apologies GDG Meeting 5 19/07/2013 Non-personal pecuniary interest: No action required. Principal investigator for two food Review on serum specific allergy studies. Thermofisher provides IgE testing presented in the testing kits.The company also GDG3 produce ImmunoCap tests for drug allergy. GDG Meeting 6 16/09/2013 No change GDG Meeting 7 04/11/2013 No change GDG Meeting 8 05/11/2013 Apologies GDG Meeting 9 10/01/2014 No change GDG Meeting 10 31/01/2014 No change GDG Meeting 11 06/06/2014 No change B.2.5 East, Mandy GDG meeting Date Declaration of Interest Action Taken GDG Application Non-personal pecuniary interest: Paid No action required. as a self-employed contractor for work on the National Allergy Strategy Group who are supported by unrestricted grants from: ALK Abello, Meda Pharma, Damone and Thermo Fisher. GDG Meeting 1 14/12/2012 No change GDG Meeting 2 25/01/2013 No change GDG Meeting 3 02/05/2013 No change GDG Meeting 4 07/06/2014 No change GDG Meeting 5 19/07/2014 No change GDG Meeting 6 16/09/2014 No change GDG Meeting 7 04/11/2013 No change National Clinical Guideline Centre, 2014 15 Drug allergy Declarations